Loading...

Inovalon Holdings

Nasdaq:INOV
Snowflake Description

Reasonable growth potential and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INOV
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Inovalon Holdings, Inc., a technology company, provides cloud-based platforms empowering data-driven healthcare. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
INOV Share Price and Events
7 Day Returns
7.5%
NasdaqGS:INOV
-0.2%
US Healthcare Services
-0.7%
US Market
1 Year Returns
39.9%
NasdaqGS:INOV
27.9%
US Healthcare Services
3%
US Market
INOV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Inovalon Holdings (INOV) 7.5% 12% -5.4% 39.9% -22.9% -
US Healthcare Services -0.2% 7.5% 8.5% 27.9% 75.8% 61.2%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • INOV outperformed the Healthcare Services industry which returned 27.9% over the past year.
  • INOV outperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
INOV
Industry
5yr Volatility vs Market
Related Companies

INOV Value

 Is Inovalon Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Inovalon Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Inovalon Holdings.

NasdaqGS:INOV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:INOV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.23
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.23 (1 + (1- 21%) (47.26%))
1.462
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.46
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.462 * 5.96%)
11.44%

Discounted Cash Flow Calculation for NasdaqGS:INOV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Inovalon Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:INOV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 11.44%)
2019 68.21 Analyst x3 61.20
2020 95.80 Analyst x1 77.13
2021 117.74 Est @ 22.9% 85.06
2022 137.58 Est @ 16.85% 89.19
2023 154.93 Est @ 12.61% 90.13
2024 169.88 Est @ 9.65% 88.67
2025 182.75 Est @ 7.57% 85.59
2026 193.93 Est @ 6.12% 81.50
2027 203.83 Est @ 5.1% 76.87
2028 212.78 Est @ 4.39% 72.00
Present value of next 10 years cash flows $807.35
NasdaqGS:INOV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $212.78 × (1 + 2.73%) ÷ (11.44% – 2.73%)
$2,508.29
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,508.29 ÷ (1 + 11.44%)10
$848.76
NasdaqGS:INOV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $807.35 + $848.76
$1,656.11
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,656.11 / 153.25
$10.81
NasdaqGS:INOV Discount to Share Price
Calculation Result
Value per share (USD) From above. $10.81
Current discount Discount to share price of $14.13
= -1 x ($14.13 - $10.81) / $10.81
-30.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Inovalon Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Inovalon Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Inovalon Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:INOV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.21
NasdaqGS:INOV Share Price ** NasdaqGS (2019-05-17) in USD $14.13
United States of America Healthcare Services Industry PE Ratio Median Figure of 13 Publicly-Listed Healthcare Services Companies 57.2x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Inovalon Holdings.

NasdaqGS:INOV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INOV Share Price ÷ EPS (both in USD)

= 14.13 ÷ -0.21

-66.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovalon Holdings is loss making, we can't compare its value to the US Healthcare Services industry average.
  • Inovalon Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Inovalon Holdings's expected growth come at a high price?
Raw Data
NasdaqGS:INOV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -66.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
140.7%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.33x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Inovalon Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Inovalon Holdings's assets?
Raw Data
NasdaqGS:INOV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.37
NasdaqGS:INOV Share Price * NasdaqGS (2019-05-17) in USD $14.13
United States of America Healthcare Services Industry PB Ratio Median Figure of 34 Publicly-Listed Healthcare Services Companies 4.38x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:INOV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INOV Share Price ÷ Book Value per Share (both in USD)

= 14.13 ÷ 4.37

3.23x

* Primary Listing of Inovalon Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovalon Holdings is good value based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess Inovalon Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Inovalon Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

INOV Future Performance

 How is Inovalon Holdings expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
140.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Inovalon Holdings expected to grow at an attractive rate?
  • Inovalon Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Inovalon Holdings's earnings growth is expected to exceed the United States of America market average.
  • Inovalon Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:INOV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:INOV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 140.7%
NasdaqGS:INOV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 8.4%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 25.2%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 11.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:INOV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:INOV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 746 2
2020-12-31 686 155 24 7
2019-12-31 636 130 3 8
NasdaqGS:INOV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 580 98 -31
2018-12-31 528 90 -39
2018-09-30 506 80 -11
2018-06-30 476 77 -2
2018-03-31 434 102 14
2017-12-31 449 98 34
2017-09-30 431 105 18
2017-06-30 420 102 17
2017-03-31 433 81 28
2016-12-31 428 93 27
2016-09-30 452 92 42
2016-06-30 453 80 45

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Inovalon Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Inovalon Holdings's revenue is expected to grow by 8.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:INOV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Inovalon Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:INOV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31 0.16 0.20 0.12 5.00
2019-12-31 0.00 0.03 -0.03 5.00
NasdaqGS:INOV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.21
2018-12-31 -0.27
2018-09-30 -0.07
2018-06-30 -0.01
2018-03-31 0.10
2017-12-31 0.24
2017-09-30 0.12
2017-06-30 0.12
2017-03-31 0.19
2016-12-31 0.18
2016-09-30 0.28
2016-06-30 0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Inovalon Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Inovalon Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Inovalon Holdings has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

INOV Past Performance

  How has Inovalon Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Inovalon Holdings's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Inovalon Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Inovalon Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Inovalon Holdings's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Inovalon Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Inovalon Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:INOV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 580.41 -31.22 246.43 30.42
2018-12-31 527.68 -39.16 236.76 28.64
2018-09-30 505.98 -10.66 241.62 28.08
2018-06-30 476.03 -1.82 230.65 26.28
2018-03-31 433.81 13.99 204.35 26.02
2017-12-31 449.36 33.83 190.69 27.38
2017-09-30 430.83 17.54 173.09 28.95
2017-06-30 419.99 17.32 169.51 30.58
2017-03-31 433.24 28.16 162.37 31.00
2016-12-31 427.59 26.94 162.05 29.15
2016-09-30 452.06 42.32 159.36 26.18
2016-06-30 452.50 44.66 152.21 25.06
2016-03-31 446.30 54.61 142.33 22.85
2015-12-31 437.27 66.01 128.21 22.33
2015-09-30 406.63 63.50 117.37 22.95
2015-06-30 387.16 67.06 105.05 22.85
2015-03-31 370.50 64.55 100.29 22.49
2014-12-31 361.54 65.35 95.45 23.13
2014-09-30 336.16 57.59 90.00 22.40
2014-06-30 325.17 53.40 86.84 21.46
2014-03-31 302.34 38.52 85.87 21.78
2013-12-31 295.80 32.72 86.59 21.19
2012-12-31 300.28 55.16 79.45 15.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Inovalon Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Inovalon Holdings used its assets less efficiently than the US Healthcare Services industry average last year based on Return on Assets.
  • It is difficult to establish if Inovalon Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Inovalon Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Inovalon Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

INOV Health

 How is Inovalon Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Inovalon Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Inovalon Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Inovalon Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Inovalon Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Inovalon Holdings Company Filings, last reported 1 month ago.

NasdaqGS:INOV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 670.29 1,023.49 121.69
2018-12-31 682.59 976.08 122.59
2018-09-30 702.02 968.50 114.89
2018-06-30 693.92 969.40 83.68
2018-03-31 631.76 241.95 450.28
2017-12-31 642.77 248.70 476.23
2017-09-30 652.09 243.99 525.66
2017-06-30 657.81 251.52 531.55
2017-03-31 665.40 259.05 533.31
2016-12-31 683.58 266.58 573.00
2016-09-30 728.62 270.35 713.32
2016-06-30 769.81 274.13 743.88
2016-03-31 750.61 277.92 738.48
2015-12-31 739.16 281.66 728.16
2015-09-30 716.90 285.36 714.09
2015-06-30 673.17 290.39 796.99
2015-03-31 646.36 295.24 793.11
2014-12-31 -8.22 300.27 162.57
2014-09-30 -23.36 300.30 131.95
2014-06-30 261.73 0.33 120.08
2014-03-31 231.73 0.41 110.59
2013-12-31 231.73 0.41 110.59
2012-12-31 236.83 0.29 106.36
  • Inovalon Holdings's level of debt (152.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 152.7% today).
  • Debt is not well covered by operating cash flow (9.6%, less than 20% of total debt).
  • Inovalon Holdings is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Inovalon Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Inovalon Holdings has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

INOV Dividends

 What is Inovalon Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Inovalon Holdings dividends. Estimated to be 0% next year.
If you bought $2,000 of Inovalon Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Inovalon Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Inovalon Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:INOV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 14 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:INOV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Inovalon Holdings has not reported any payouts.
  • Unable to verify if Inovalon Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Inovalon Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Inovalon Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Inovalon Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Inovalon Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Inovalon Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Inovalon Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

INOV Management

 What is the CEO of Inovalon Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Keith Dunleavy
COMPENSATION $210,325
AGE 49
TENURE AS CEO 5.3 years
CEO Bio

Dr. Keith R. Dunleavy, M.D., has been the Chairman of Inovalon Holdings, Inc. since 2006 and its Chief Executive Officer since 1998. Dr. Dunleavy is responsible for the overall execution of Inovalon Holdings, Inc.’s business plan, expansion of strategic relationships and the identification and realization of Company product strategy and vision. He served as the President of Inovalon, Inc. until May 19, 2014. During his tenure at Inovalon, He has worked extensively with a wide array and number of healthcare organizations, regulatory and oversight bodies and technology companies examining the growing role of data within healthcare and its ability to drive meaningful insight and improvement for its constituents. Driven by a vision of data's ability to drive insight and improvement in healthcare, He led Inovalon from its origins to its current industry-leading position leveraging advanced, cloud-based analytical and data-driven intervention platforms. Prior to organizing predecessor companies of Inovalon, Dr. Dunleavy worked in areas of management consulting designed to leverage the benefits of multidisciplinary personnel teams with prowess within the basic sciences, software technology, business strategy, finance and operational scaling. In this role, he has served in a wide range of design, strategy and management positions for an array of basic science research, corporate development initiatives and private equity projects. He has been a Director of Inovalon Holdings, Inc. since 2006. He serves as a Director of Board of Overseers at Dartmouth Medical School. He has authored or co-authored a number of scientific journal articles, abstracts and proprietary research papers and has presented his work and materials at multiple national and international conferences. He received a Bachelor’s degree in Biology modified with Engineering with High Honors from Dartmouth College where his thesis work focused on applications of computer-simulated artificial human cerebellar functional units. Dr. Dunleavy earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, practiced and was Board Certified in Internal Medicine.

CEO Compensation
  • Keith's compensation has increased whilst company is loss making.
  • Keith's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Inovalon Holdings management team in years:

1.5
Average Tenure
47.5
Average Age
  • The average tenure for the Inovalon Holdings management team is less than 2 years, this suggests a new team.
Management Team

Keith Dunleavy

TITLE
Chairman & CEO
COMPENSATION
$210K
AGE
49
TENURE
5.3 yrs

Bob Wychulis

TITLE
President
COMPENSATION
$2M
AGE
63
TENURE
5 yrs

Jonathan Boldt

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
33
TENURE
1.2 yrs

Jason Capitel

TITLE
Chief Operating Officer
COMPENSATION
$8M
AGE
46
TENURE
1.1 yrs

Mike Burgin

TITLE
Chief Product Officer
COMPENSATION
$1M
AGE
44
TENURE
1.5 yrs

Peter De Bock

TITLE
Chief Administrative Officer
AGE
55
TENURE
0.3 yrs

George Price

TITLE
Investor Relations

Kim Collins

TITLE
Senior Vice President of Corporate Marketing & Communications

Eric Sullivan

TITLE
Senior Vice President of Innovation & Data Strategies

John Spitz

TITLE
Senior Vice President of Business Solutions & Sales
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the Inovalon Holdings board of directors in years:

6.8
Average Tenure
64.5
Average Age
  • The tenure for the Inovalon Holdings board of directors is about average.
Board of Directors

Keith Dunleavy

TITLE
Chairman & CEO
COMPENSATION
$210K
AGE
49
TENURE
13.3 yrs

Denise Fletcher

TITLE
Independent Director
COMPENSATION
$250K
AGE
69
TENURE
7.3 yrs

Lee Roberts

TITLE
Independent Director
COMPENSATION
$250K
AGE
65
TENURE
7.3 yrs

Bill Teuber

TITLE
Independent Director
COMPENSATION
$250K
AGE
66
TENURE
6.3 yrs

Bill Green

TITLE
Independent Director
COMPENSATION
$250K
AGE
64
TENURE
2.8 yrs

André Hoffmann

TITLE
Independent Director
COMPENSATION
$250K
AGE
60
TENURE
11.3 yrs

Mark Pulido

TITLE
Non-Independent Director
COMPENSATION
$231K
AGE
65
TENURE
1.1 yrs

Zak Kohane

TITLE
Independent Director
AGE
57
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Inovalon Holdings insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. May 19 Buy Keith Dunleavy Individual 10. May 19 14. May 19 136,995 $13.60 $1,836,955
14. Nov 18 Buy Jason Capitel Individual 13. Nov 18 13. Nov 18 20,000 $11.06 $221,100
11. Jun 18 Buy Lee Roberts Individual 08. Jun 18 08. Jun 18 10,000 $10.54 $105,400
X
Management checks
We assess Inovalon Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Inovalon Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

INOV News

Simply Wall St News

Are Inovalon Holdings, Inc. (NASDAQ:INOV) Investors Paying Above The Intrinsic Value?

We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $68.21 $95.80 $117.74 $137.58 $154.93 $169.88 $182.75 $193.93 $203.83 $212.78 Growth Rate Estimate Source Analyst x3 Analyst x1 Est @ 22.9% Est @ 16.85% Est @ 12.61% Est @ 9.65% Est @ 7.57% Est @ 6.12% Est @ 5.1% Est @ 4.39% Present Value ($, Millions) Discounted @ 11.48% $61.18 $77.09 $84.98 $89.08 $89.99 $88.51 $85.41 $81.30 $76.65 $71.78 Present Value of 10-year Cash Flow (PVCF)= $805.96m "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$213m × (1 + 2.7%) ÷ (11.5% – 2.7%) = US$2.5b Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$2.5b ÷ ( 1 + 11.5%)10 = $842.74m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $1.65b.

Simply Wall St -

Do Directors Own Inovalon Holdings, Inc. (NASDAQ:INOV) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that. … See our latest analysis for Inovalon Holdings

Simply Wall St -

Imagine Owning Inovalon Holdings (NASDAQ:INOV) And Wondering If The 34% Share Price Slide Is Justified

(NASDAQ:INOV) shareholders have had that experience, with the share price dropping 34% in three years, versus a market return of about 50%. … Shareholders have had an even rougher run lately, with the share price down 10% in the last 90 days. … Over the three years that the share price declined, Inovalon Holdings's earnings per share (EPS) dropped significantly, falling to a loss.

Simply Wall St -

Inovalon Holdings, Inc. (NASDAQ:INOV) Insiders Increased Their Holdings

So we'll take a look at whether insiders have been buying or selling shares in Inovalon Holdings, Inc. … The Last 12 Months Of Insider Transactions At Inovalon Holdings. … In the last twelve months there was more buying than selling by Inovalon Holdings insiders

Simply Wall St -

Is Inovalon Holdings, Inc.'s (NASDAQ:INOV) CEO Paid At A Competitive Rate?

Keith Dunleavy became the CEO of Inovalon Holdings, Inc. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Keith Dunleavy's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What does Inovalon Holdings, Inc.'s (NASDAQ:INOV) Balance Sheet Tell Us About Its Future?

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Inovalon Holdings, Inc. … Let’s take a look at INOV’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Take the survey and be part of one of the most advanced studies of stock market investors to date

Simply Wall St -

Is Inovalon Holdings, Inc. (NASDAQ:INOV) A Financially Sound Company?

(NASDAQ:INOV) with its market cap of US$1.9b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Did Inovalon Holdings Inc (NASDAQ:INOV) Insiders Buy Up More Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Inovalon Holdings Inc (NASDAQ:INOV). … The Last 12 Months Of Insider Transactions At Inovalon Holdings. … In the last twelve months insiders purchased 148.00k shares for US$1.5m.

Simply Wall St -

Who Owns Most Of Inovalon Holdings Inc (NASDAQ:INOV)?

I am going to take a deep dive into Inovalon Holdings Inc’s (NASDAQ:INOV) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

How Financially Strong Is Inovalon Holdings Inc (NASDAQ:INOV)?

Inovalon Holdings Inc (NASDAQ:INOV) is a small-cap stock with a market capitalization of US$1.53b. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

INOV Company Info

Description

Inovalon Holdings, Inc., a technology company, provides cloud-based platforms empowering data-driven healthcare. It operates the Inovalon ONE Platform, a cloud-based platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately 964,000 physicians; 519,000 clinical facilities; and approximately 264 million individuals and 42 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland.

Details
Name: Inovalon Holdings, Inc.
INOV
Exchange: NasdaqGS
Founded: 1998
$2,165,436,149
153,250,966
Website: http://www.inovalon.com
Address: Inovalon Holdings, Inc.
4321 Collington Road,
Bowie,
Maryland, 20716,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INOV Class A Common Stock Nasdaq Global Select US USD 12. Feb 2015
DB IOV Class A Common Stock Deutsche Boerse AG DE EUR 12. Feb 2015
Number of employees
Current staff
Staff numbers
2,302
Inovalon Holdings employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 03:08
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.